Cancer Screening, Surrogates of Survival, and the Soma

Cancer Cell. 2020 Oct 12;38(4):433-437. doi: 10.1016/j.ccell.2020.09.003. Epub 2020 Sep 17.

Abstract

Screening leads to meaningful reductions in deaths from cancers. However, reductions in all-cause mortality (ACM) are harder to demonstrate. Failure to demonstrate ACM benefit should not diminish advances in cancer screening. We consider how co-morbidities related to an aging and damaged soma can hinder achievement of ACM benefit.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aging
  • Cause of Death
  • Early Detection of Cancer / methods*
  • Neoplasms / diagnosis*
  • Neoplasms / mortality
  • Neoplasms / therapy*
  • Risk Assessment
  • Risk Factors
  • Smoking
  • Survival Analysis
  • Survival Rate